In a report released today, Jeffrey Hung from Morgan Stanley maintained a Hold rating on Intra-Cellular Therapies (ITCI – Research Report), ...

Fintel reports that on January 31, 2025, Canaccord Genuity downgraded their outlook for Intra-Cellular Therapies ...

In a report released on January 27, Jessica Fye from J.P. Morgan maintained a Buy rating on Intra-Cellular Therapies (ITCI – Research Report), ...

Below is Validea's guru fundamental report for INTRA-CELLULAR THERAPIES INC (ITCI). Of the 22 guru strategies we follow, ITCI rates highest using our Value Investor model based on the published ...

We recently compiled a list of the Why These 15 Stocks Are Skyrocketing in 2025. In this article, we are going to take a look at where Intra-Cellular Therapies (NASDAQ:ITCI) stands against the other ...

In this article, we are going to take a look at where Intra-Cellular Therapies (NASDAQ:ITCI) stands against the other stocks. Stock gains always get people talking, and 2025 is no exception.

Fintel reports that on January 22, 2025, RBC Capital downgraded their outlook for Intra-Cellular Therapies (NasdaqGS:ITCI) from Outperform to Sector Perform. Analyst Price Forecast Suggests 17.02% ...

Shares of ITCI opened at $127.15 on Wednesday. Intra-Cellular Therapies has a 12 month low of $62.78 and a 12 month high of $128.00. The firm has a fifty day simple moving average of $90.75 and a ...